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Abstract. Handigodu Disease (HD) is disorder of the osteoarticular system prevalent in few villages of two districts of the state
Karnataka in southern India. 24 hrs urinary excretions of proline (Pro) and 4-hydroxyproline (Hyp) were analyzed by HPLC.
Decreased peptide bound Hyp excretions (µmole/24 hrs) were found in patient group when compared with controls (Nonaffected;
113.02± 67.96, Type-I; 36.22± 20.76, Type-II; 45.74± 14.95, Type-III; 40.46± 22.68) and without significant difference in Pro
excretions. Significant increased peptide bound Pro to Hyp ratio were found in patient group compared to control (Nonaffected
n = 63: 2.02 ± 1.65, Type-I n = 18: 3.144 ± 1.42, Type-II n = 28: 4.21 ± 1.95, Type-III n = 8: 8.60 ± 6.55). 24 hrs
urinary excretions of deoxypyridinoline (DPD) crosslinks were found without significant difference among affected and control,
hence HD ruled out from general bone reduction. These results suggest hypohydroxyprolinuria may be because of reduced bone
turnover or defective hydroxylation of prolyl residues during post translational modification of collagen biosynthesis.
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1. Introduction
Handigodu Disease (HD) is a disorder of the osteoar-
ticular system prevalent in several villages of two dis-
tricts Shimoga and Chickmaglur in the state of Kar-
nataka, southern India. The disease was first identified
in a patient from Handigodu village in 1975, hence its
name [1]. HD is a spondylo epi(meta)physeal dyspla-
sia inherited as an autosomal dominant trait and iden-
tified to be of three types viz., Arthritic type (Type-I),
Dysplastic type (Type-II) and Dwarf type (Type-III).
All three types segregate in the same families.
The symptoms usually start in young adulthood with
pain in hip joints area and difficulty in walking and
running. The onset is insidious and course progressive,
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significantly handicapped with osteoarthritis of the hip
joints by 35–45 yrs of age. Fixed flexion deformity
of hips, lumbar lordosis, waddling gait, difficulty in
squatting and sitting cross-legged are more common in
patients. Type I individuals are usually of normal height
and proportions, Type II individuals have significant
truncal shortening and marked platyspondyly and Type
III individuals are dwarf and show epiphyseal dysplasia
at knee, wrists and other joints [2,3].
The major groups of spondyloepiphyseal dysplasias
which were similar to HD are SED congenita, SED
tarda and pseudoachondrodysplasia. HD is different
from these dysplasias in several aspects either clinical
presentation or in X-ray analysis [2]. The Namaqua-
land hip dysplasia is an autosomal dominant SED tar-
da, from South Africa has similar clinical presentation
to HD. Posterior hump in spine is absent and knees
were not been deformed in Namaqualand hip dyspla-
sia has made a differ from HD. The disease found in
South Africa namely MSeleni joint disease had clinical
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Table 1
Urinary excretion of Total amino acids, Free amino acids in Handigodu patients in relation to 24 hrs
urine volume and creatinine
Nonaffected Type-I Type-II Type-III
mmoles / 24 hrs
Total amino acids 18.63 ± 5.76 18.21 ± 4.48 22.01 ± 10.29 20.78 ± 10.92
Free amino acids 5.68 ± 2.59 5.08 ± 1.84 6.61 ± 2.71 5.16 ± 1.68
Peptide bound amino acids 12.94 ± 4.15 12.63 ± 3.93 13.5 ± 8.24 12.82 ± 4.11
mmoles / mmole cratinine
Total amino acids 5.46 ± 2.11 5.26 ± 1.76 4.15 ± 1.53 5.33 ± 2.89
Free amino acids 1.63 ± 1.30 1.658 ± 0.741 1.346 ± 0.408 1.387 ± 0.518
Peptide bound amino acids 3.83 ± 1.56 3.63 ± 1.29 3.5 ± 1.36 4.07 ± 2.58
presentations similar to HD. The only difference ob-
served is rheumatoid arthritis like changes in metacar-
pophalanges and absence of posterior hump in spine in
MSeleni joint disease [2]. In comparison to Stickler
syndrome, HD has not affect before 5 years of age and
did not manifests symptoms like cleft palate, myopia,
micrognathia, reital detachment and hearing loss [4,5].
The varied clinical presentation and X- ray analysis of
HD with other bone disorders promptly made to look
into collagen metabolism.
2. Materials and methods
2.1. Subjects
The HD affected patients clinically and x-ray radi-
ologically confirmed (Type-I; n = 19, Type-II; n =
28. Type-III; n = 8.) have been selected for this study
under the age group of 20–60 years old with their con-
sent. Sixty three (Nonaffected: n = 63) healthy in-
dividuals with age group of 20–60 years old from the
non related family members of HD affected were en-
rolled in this study as controls. All the controls clinical
and by x-ray diagnosis were normal. Both the affect-
ed and control groups have been provided normal food
that has not contain any collagen products during the
study. The subjects were asked to empty their bladder
before the experiments of 24 hrs urine collection start-
ed. The 24 hours urine was collected using Conc HCl
as preservative to avoid microbial deterioration.
2.2. Biochemical markers
The 24 hour urine samples were collected and stored
at –20◦C until they were analyzed. The urinary ex-
cretion of creatinine has been assayed by autosampler
in the department. (Hitachi 905). Excretions of De-
oxypyridinoline (DPD) crosslinks levels in urine were
determined by DPC Immulite-2000 reagents and relat-
ed to 24 hrs urine volume. The urine has been subjected
to alkaline hydrolysis to analyze total proline (Pro), to-
tal hydroxyproline (Hyp) and total amino acids excret-
ed. Free proline, free Hydroxyproline and free amino
acids excreted were assayed without hydrolysis. The
peptide bound proline, peptide bound hydroxyproline,
and peptide bound amino acids were calculated by de-
ducting free from total. The peptide bound Pro and Hyp
were made free by the hydrolysis of urine following
the procedure of M. Badadani et al. [6]. Pro and Hyp
were analyzed using HPLC by Dinitrophenyl derivati-
zation using methanol and acetate buffer gradient. The
Amino acids were quantified by using the method of
DNFB [7,8]. The total as well as peptide bound Hyp,
Pro and amino acids excreted were calibrated to 24 hrs
urine volume collected and, Pro and Hyp were related
to creatinine and amino acids.
2.3. Statistical analysis
The Data were analyzed using SPSS programme of
Windows 2000 and statistical significance of the cor-
relation was determined with one- way ANOVA fol-
lowed by Post Hoc, Bonferroni T-test. The P values
indicate significance level of differences between the
means at point. The probability values less than 0.05
were considered statistically significant.
3. Results
The excretion of Deoxypyridinoline (DPD) crossl-
inks (µmole/24 hrs) {Nonaffected: 44.28 ± 27.99,
Type-I: 46.62± 15.7, Type-II: 49.87± 16.03, Type-III:
51.03± 16.22} values found without significant differ-
ence as shown in Fig. 1. Since comparison of Excre-
tions of free amino acids, free Pro and free Hyp between
affected and unaffected groups have not shown signifi-
cant difference and data were presented in Tables 1 and
2.
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Fig. 1. A. 24 hrs urinary excretions of deoxypyridinoline (DPD) crosslinks among Nonaffected and affected subtypes showing without significant
difference. B. 24 hrs urinary excretions of peptide derived hydroxyproline among Nonaffected and clinical subtypes showing significant difference
with depleted levels in HD affected. C. Urinary excretions of peptide derived proline / hydroxyproline ratio among unaffected and affected
subtypes showing significant difference with elevated levels in HD affected.
The Excretions of total as well as peptide bound
amino acids, Pro and Hyp were presented in Ta-
ble 2.The values have related to aminoacids, creatinine
excreted and 24 hrs urine volume collected. The af-
fected groups have excreted depleted level of Hyp in
comparison with unaffected group. The values of ratio
between Pro and Hyp were compared and found to be
significantly higher in affected groups than control with
p < 0.05 (Fig. 2).
4. Discussion
The Hydroxyproline (Hyp) constitutes 12–14%
amino acid content of matured collagens, but only 10%
released during the bone resorption reaches the urine
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Table 2
Urinary excretion of Total Proline, Total Hydroxyproline Free Proline, free Hydroxyproline, peptide
bound proline, peptide bound hydroxyproline Pro / Hyp Ratio in relation to 24 hrs urine volume (table
2A), creatinine (table2B) and amino acids (table2C) excreted in Handigodu patients
Panel A Nonaffected Type-I Type-II Type-III
m mole / 24 HRS
Total Proline 177.80 ± 61.44 124.19 ± 74.5 189.05 ± 88.04 188.09 ± 111.97
p = 0.002 p = 0.495 p = 0.691
Free Proline 19.52 ± 11.90 18.57 ± 8.85 40.69 ± 18.5 33.18 ± 26.82
p = 0.741 p < 0.001 p = 0.010
Peptide bound Proline 159.18 ± 60.70 136.23 ± 68.38 168.93 ± 69.89 128.97 ± 39.16
p = 0.164 p = 0.458 p = 0.176
Total Hyp 115.09 ± 64.99 37.43 ± 21.34 48.65 ± 17.55 42.23 ± 23.01
p < 0.001 p < 0.001 p = 0.002
Free Hyp 3.09 ± 1.80 1.86 ± 1.23 3.67 ± 1.72 2.00 ± 0.61
p = 0.06 p = 0.154 p = 0.09
Peptide bound Hyp 113.02 ± 67.96 36.22 ± 20.76 45.74 ± 14.95 40.46 ± 22.68
p < 0.001 p < 0.001 p = 0.003
Pro/Hyp Ratio 1.86 ± 1.17 3.41 ± 1.72 3.99 ± 1.55 3.39 ± 1.67
(Total) p < 0.001 p < 0.001 p = 0.001
Pro/Hyp Ratio 2.02 ± 1.65 3.144 ± 1.42 4.21 ± 1.95 8.60 ± 6.55
(peptide bound) p = 0.009 p < 0.001 p < 0.001
Panel B Nonaffected Type-I Type-II Type-III
µ mole / m mole CREATININE
Total Proline 50.55 ± 31.81 35.53 ± 25.44 35.98 ± 19.11 29.95 ± 10.59
Free Proline 5.40 ± 3.39 4.75 ± 1.83 6.48 ± 3.40 3.80 ± 1.68
Peptide bound Proline 45.93 ± 31.15 35.07 ± 20.15 36.04 ± 18.48 38.35 ± 14.94
Total Hyp 34.48 ± 27.81 11.97 ± 8.62 9.23 ± 3.46 8.85 ± 4.17
Free Hyp 0.52 ± 0.30 0.862 ± 0.851 0.923 ± 0.633 0.371 ± 0.223
Peptide bound Hyp 33.47 ± 27.52 12.80 ± 8.44 8.54 ± 3.33 9.62 ± 3.12
Pro/Hyp Ratio 1.86 ± 1.56 3.29 ± 1.74 3.92 ± 1.57 3.39 ± 1.67
(Total)
Pro/Hyp Ratio 2.00 ± 1.64 3.43 ± 1.45 4.14 ± 1.95 8.24 ± 6.79
(peptide bound)
Panel C Nonaffected Type-I Type-II Type-III
µ mole / m mole Amino acids
Total Proline 10.55 ± 5.48 8.11 ± 5.19 9.89 ± 4.56 9.08 ± 2.8
Free Proline 3.26 ± 1.96 3.74 ± 2.37 5.38 ± 2.05 4.98 ± 3.32
Peptide bound Proline 7.41 ± 5.83 6.52 ± 3.98 8.57 ± 4.15 8.75 ± 2.85
Total Hyp 6.82 ± 5.20 2.46 ± 1.47 2.61 ± 0.99 2.42 ± 1.67
Free Hyp 1.14 ± 0.73 1.48 ± 1.03 3.95 ± 1.77 2.009 ± 0.61
Peptide bound Hyp 6.18 ± 4.97 1.76 ± 1.39 2.14 ± 1.08 1.83 ± 0.87
Pro/Hyp Ratio 1.85 ± 1.49 3.50 ± 1.74 3.99 ± 1.55 3.39 ± 1.67
(Total)
Pro/Hyp Ratio 2.05 ± 1.89 3.5 ± 1.73 3.99 ± 1.55 8.23 ± 6.16
(peptide bound)
in free or peptide forms [9]. Since most of the Hyp
of body is found in collagen and suggested that uri-
nary excretion of this imino acid may be an important
index of collagen metabolism [10–12]. The isotopic
studies of Stetten in rats indirectly suggested that most
of the free and peptide bound Hyp in the body arises
from the breakdown of collagen, since she found that
hyp-N15 was not significantly incorporated into colla-
gen [13]. The diurnal variation, hydration and dehy-
dration did not alter excretion of Hyp. The ingestion
of large amounts of Hyp as free imino acid resulted
in an increased excretion of free but not in the peptide
form which normally accounts for nearly all of Hyp
in urine [10,12]. Westall described a peptide contain-
ing equal amounts of Pro and Hyp and the bound Hyp
form that predominates in human urine [14]. The urine
of a patient with rheumatoid arthritis had shown two
hyp bound peptides [15]. The study has been made
of peptide excretion in Wilson’s disease, excess output
of peptide was shown to consist of Hyp peptides de-
rived from collagen degradation was highly statistically
significant [16].
The 24 hrs urinary excretions of DPD crosslinks have
shown without significant difference, hence HD has
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been ruled out from general reduction of bone resorp-
tion. The values for excretions of Pro and amino acids
either in total, free or peptide form found without sig-
nificant difference. The free Hyp excreted were also
found to be normal. Hence their diet and diurnal vari-
ation have not been influenced on the excretion of Pro
and Hyp in HD. The depleted levels of Hyp in 24 hrs
urine, in relation to creatinine and amino acids excret-
ed either in total form or peptide bound (Nonaffected:
113.02± 67.96 µ mole / 24hrs, TypeI: 36.22± 20.76 µ
mole / 24 hrs, Type II:45.74 ± 14.95 µ mole / 24hrs,
TypeIII: 40.46 ± 22.68 µ mole / 24hrs) were observed
in affected group. In addition increased Pro/Hyp ratios
were observed in HD group as compoared to unaffect-
ed group (Fig. 1). The results are consistent with the
hypothesis that large hyp excretions found in rheumatic
diseases Marfan’s syndrome and Stickler syndrome [4,
10,11]. For many years, measurement of 24 hrs or sec-
ond morning void urinary Hyp / creat has been used
successfully as an index of bone collagen resorption.
Elevated levels of hyp urinary excretions have been
found in Paget disease [17]. A variety of biochemi-
cal tests reflecting bone matrix resorption provide good
indices of disease activity. Handigodu Disease is the
only first most disease reporting lesser excretions of
Hydroxyproline in urine compared to other bone disor-
ders like Marfan’s syndrome, Paget disease, secondary
hyperthyroidism rheumatoid arthritis and Stickler syn-
drome that have shown elevated levels.
The peptide bound hypohydroxyprolinuria and in-
creased Pro / Hyp ratio suggests HD may involve re-
duced bone turnover or a possible defective hydroxyla-
tion of prolyl residues during posttranslational modifi-
cation of collagen molecule biosynthesis. Hence pos-
sible defect in prolyl-4- hydroxylases activity and pos-
sible defect in collagen assembly as Hyp is necessary
for the stability of collagen molecule [18]. Apart from
hypohydroxyprolinuria, HD has shown hypocalcitone-
mia (manuscript submitted). Hence HD appears to be
a multigene disorder with varied involvement of genes
and clinical presentation.
The limitation of study is that Pro and Hyp excre-
tion levels analysis should be extended to other dys-
plasia bone disorders and follow up study is needed to
understand progression of severity in HD.
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